These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20567105)

  • 21. A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.
    Grønberg BH; Bremnes RM; Aasebø U; Brunsvig P; Fløtten O; Amundsen T; von Plessen C; Wang M; Sundstrøm S;
    Lung Cancer; 2009 Jan; 63(1):88-93. PubMed ID: 18538889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of adverse events of amrubicin hydrochloride for pretreated lung cancer patients].
    Takase M; Maruoka H; Maeda R; Shibata K
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1789-92. PubMed ID: 18030011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
    Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
    Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.
    Asao T; Nokihara H; Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Yamamoto N; Sekine I; Kunitoh H; Fujiwara Y; Ohe Y
    Jpn J Clin Oncol; 2015 Oct; 45(10):941-6. PubMed ID: 26232449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of adriamycin, etoposide plus ifosfamide on small cell lung cancer--a retrospective analysis of 69 cases treated in Centre Hospitalo-Universitaire de Bordeaux].
    Su Y
    Ai Zheng; 2006 Dec; 25(12):1569-72. PubMed ID: 17166389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amrubicin monotherapy for elderly patients with previously treated lung cancer.
    Nakao M; Oguri T; Suzuki T; Kunii E; Tomita Y; Iwashima Y; Miyazaki M; Maeno K; Sato S; Ueda R
    Intern Med; 2010; 49(17):1857-62. PubMed ID: 20823645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
    Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
    Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer.
    Mori K; Kamiyama Y; Kondo T; Kano Y; Kodama T
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):86-90. PubMed ID: 16447041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung.
    Yoshida H; Sekine I; Tsuta K; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
    Jpn J Clin Oncol; 2011 Jul; 41(7):897-901. PubMed ID: 21636606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer.
    Ikeda J; Maruyama R; Okamoto T; Shoji F; Wataya H; Ichinose Y
    Jpn J Clin Oncol; 2006 Jan; 36(1):12-6. PubMed ID: 16418184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
    Rhee CK; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim CH; Shim BY; Kim HK; Sun DS; Kim KH
    Lung Cancer; 2011 Apr; 72(1):64-7. PubMed ID: 20832894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.
    Igawa S; Yamamoto N; Ueda S; Ono A; Nakamura Y; Tsuya A; Murakami H; Endo M; Takahashi T
    J Thorac Oncol; 2007 Aug; 2(8):741-4. PubMed ID: 17762341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
    Sone H; Igawa S; Kasajima M; Ishihara M; Hiyoshi Y; Hosotani S; Ohe S; Ito H; Kaizuka N; Manaka H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Thorac Cancer; 2018 Oct; 9(10):1279-1284. PubMed ID: 30126051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
    Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
    Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
    Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G
    Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
    Kawashima Y; Inoue A; Sugawara S; Oizumi S; Maemondo M; Okudera K; Suzuki T; Usui K; Harada M; Morikawa N; Hasegawa Y; Saito R; Ishimoto O; Sakakibara T; Asahina H; Nukiwa T
    Respir Investig; 2014 May; 52(3):190-4. PubMed ID: 24853020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
    Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E
    Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.